Online citations, reference lists, and bibliographies.

Clinical Pharmacokinetics And Pharmacodynamics Of The Oral Direct Thrombin Inhibitor Dabigatran Etexilate

J. Stangier
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The direct thrombin inhibitor dabigatran etexilate is currently in phase III of development for the prophylaxis and treatment of thromboembolic disorders, with three trials completed in primary venous thromboembolism (VTE) prevention. Dabigatran etexilate is an orally administered prodrug, which is rapidly absorbed and converted to the active form, dabigatran. Dabigatran has been shown to specifically and reversibly inhibit thrombin, the key enzyme in the coagulation cascade. Studies in healthy volunteers and in patients undergoing orthopaedic surgery have indicated that dabigatran has a predictable pharmacokinetic/pharmacodynamic profile, allowing for a fixed-dose regimen. Peak plasma concentrations of dabigatran are reached approximately 2 hours after oral administration in healthy volunteers, with no unexpected accumulation of drug concentrations upon multiple dosing. Excretion is predominantly via the renal route as unchanged drug. Dabigatran is not metabolized by cytochrome P450 isoenzymes. The small differences in dabigatran pharmacokinetics associated with age and gender are attributed to variations in renal function. Additional studies have shown that the pharmacokinetic/pharmacodynamic profile of dabigatran is consistent across a range of patient populations, with no effect of moderate hepatic impairment being observed. Drug-drug interactions are not observed with concomitant administration of atorvastatin, diclofenac or digoxin. The pharmacodynamic profile of dabigatran demonstrates effective anticoagulation combined with a low risk of bleeding. Further phase III studies are ongoing, including acute VTE treatment and stroke prevention in atrial fibrillation; the results obtained so far show that dabigatran etexilate is well tolerated and effective in the treatment and prevention of thromboembolic events.
This paper references
10.1177/0091270005274550
Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement
J. Stangier (2005)
10.1001/ARCHINTE.162.16.1833
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
A. Turpie (2002)
10.1055/S-2002-35292
Hirudin as alternative anticoagulant--a historical review.
F. Markwardt (2002)
10.1111/J.1365-2125.2006.02667.X
Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.
Karl-Heinz Liesenfeld (2006)
10.2165/00003088-200847010-00005
Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects
J. Stangier (2008)
10.1001/ARCHINTE.163.7.759
Management of venous thromboembolism: past, present, and future.
T. Hyers (2003)
10.1055/S-2005-916163
Pharmacokinetics and pharmacodynamics of ximelagatran.
M. Wolzt (2005)
10.1016/S0140-6736(96)07492-2
Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study
C. Murray (1997)
10.1111/j.1538-7836.2007.02526.x
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis
W. Wienen (2007)
10.1111/j.1538-7836.2007.02549.x
VKORC1: molecular target of coumarins
J. Oldenburg (2007)
10.1055/S-2003-44457
Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions.
A. Wittkowsky (2003)
10.1111/J.1365-2125.2007.02899.X
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
J. Stangier (2007)
10.1021/JM0109513
Structure-based design of novel potent nonpeptide thrombin inhibitors.
N. Hauel (2002)
10.1016/J.ARTH.2008.01.242
The Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, is Effective and Safe for Prevention of Major Venous Thromboembolism After Major Orthopedic Surgery
M. Huo (2008)
10.1111/j.1538-7836.2004.00890.x
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I
B. Eriksson (2004)
10.1038/sj.tpj.6500458
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis
A. Kindmark (2008)
10.1111/j.1538-7836.2004.01100.x
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial
B. Eriksson (2005)
10.1517/13543784.16.5.563
Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease
M. Husmann (2007)
10.1016/j.clpt.2004.11.001
Pharmacokinetics of Ximelagatran and Relationship to Clinical Response in Acute Deep Vein Thrombosis
M. Cullberg (2005)
10.1016/S0049-3848(98)00192-3
Synthetic inhibitors of thrombin and factor Xa: from bench to bedside.
J. Hauptmann (1999)
10.1378/CHEST.126.3_SUPPL.188S
Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
J. Hirsh (2004)
10.1177/0091270006297228
Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery
I. Trocóniz (2007)
10.1124/dmd.107.019083
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
S. Blech (2008)
10.1056/NEJMRA044440
Direct thrombin inhibitors.
M. Di Nisio (2005)
10.1160/TH07-03-0183
In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
W. Wienen (2007)
10.1016/S0049-3848(03)00249-4
The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
D. Gustafsson (2003)
10.1111/j.1538-7836.2007.02753.x
Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants
M. Samama (2007)



This paper is referenced by
10.1016/j.chest.2018.07.040
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report
G. Lip (2018)
10.1053/j.seminhematol.2014.03.005
Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Carl-Erik Dempfle (2014)
10.1007/s40265-017-0699-z
Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation
Hannah A. Blair (2017)
10.1161/JAHA.118.010854
Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion
Bruce A Warden (2018)
10.1177/2399369318809102
Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: A position paper from the Cancer & the Kidney International Network
V. Launay-Vacher (2018)
10.1182/blood-2009-09-241851
The new oral anticoagulants.
D. García (2010)
10.1016/j.jacc.2013.07.104
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
P. Reilly (2014)
10.1053/j.ajkd.2012.08.047
Removal of dabigatran by hemodialysis.
Don N. Chang (2013)
10.1111/j.1365-2125.2011.04060.x
New anticoagulants: how to deal with treatment failure and bleeding complications.
R. Kazmi (2011)
10.1016/j.ijcard.2016.07.271
Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand.
K. Bedeir (2016)
10.1097/MBC.0000000000000327
Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients
R. Pathak (2015)
10.1053/j.ajkd.2013.02.361
Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose.
B. Chen (2013)
10.1155/2013/973710
New Oral Anticoagulants in the Treatment of Pulmonary Embolism: Efficacy, Bleeding Risk, and Monitoring
Kelly M. Rudd (2013)
10.1186/1477-9560-11-10
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
W. Mueck (2013)
10.1161/CIRCULATIONAHA.111.029017
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex ConcentrateClinical Perspective
E. Eerenberg (2011)
10.1111/ans.12078
Thrombin inhibitors: surgical considerations and pharmacology
O. Breik (2013)
10.1002/clc.22173
Oral Anticoagulants to Reduce the Risk of Stroke in Atrial Fibrillation: How Should a Clinician Choose?
I. Mohammed (2013)
10.1371/journal.pone.0034354
Rational Design and Characterization of D-Phe-Pro-D-Arg-Derived Direct Thrombin Inhibitors
A. C. Figueiredo (2012)
10.1160/TH17-06-0429
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
Jacqueline M. L. Halton (2017)
10.1016/J.RCE.2010.05.016
Exantema por dabigatrán
J. Cucurull i Canosa (2010)
10.5482/HAMO-13-02-0005
Do novel oral anticoagulants do better than standard therapy in the treatment of deep vein thrombosis?
Marianne Brodmann (2013)
10.1080/00304948.2014.922383
A Novel One-pot Synthesis of 3-[(3-Amino-4-methylaminobenzoyl pyridin-2-yl)amino]propionic Acid Ethyl Ester
Ya-Jun Guo (2014)
Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial
Ahmad Mirdamadi (2014)
10.1007/s40264-017-0567-5
Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs
Ipek Komsuoglu Celikyurt (2017)
10.1016/J.CPHA.2017.06.003
Anticoagulation: The Successes and Pitfalls of Long-Term Management
Eric W. Cucchi (2017)
[Dabigatran, a new oral anticoagulant].
S. Uchiyama (2011)
10.1161/ATVBAHA.110.203604
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
W. Eisert (2010)
10.1007/s00228-013-1550-4
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma
J. Antovic (2013)
10.3109/15563650.2014.900179
Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose
A. Chiew (2014)
Heart Association Stroke Council , Council on Quality of Care and Outcomes Research , Council on Cardiovascular Nursing , Council on Clinical Cardiology , and Council on Peripheral Vascular
K. Furie (2013)
10.4172/2376-0419.1000178
Risk Factors for Bleeding Events with Enoxaparin, Dabigatran and Fondaparinux in Hospitalized Patients with Varying Levels of Renal Impairment
Tania Ahuja (2017)
10.1177/1074248410366448
Review: Will Warfarin Ever Be Replaced?
Christian T. Ruff (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar